Tarsus Pharmaceuticals, Inc.

NasdaqGS TARS

Tarsus Pharmaceuticals, Inc. Inventory for the quarter ending September 30, 2024: USD 2.85 M

Tarsus Pharmaceuticals, Inc. Inventory is USD 2.85 M for the quarter ending September 30, 2024, a 18,873.33% change year over year. Inventory is the value of goods held by a company for sale or used in the production process.

Tarsus Pharmaceuticals, Inc. Inventory for the quarter ending September 30, 2023 was USD 15.00 K, a 100.38% change year over year.
Tarsus Pharmaceuticals, Inc. Inventory for the quarter ending September 30, 2022 was USD -4.00 M.
Tarsus Pharmaceuticals, Inc. Inventory for the quarter ending September 30, 2020 was USD 432.00 K.

Key data

Date	Inventory	Goodwill	Total Assets	Current Liabilities

NasdaqGS: TARS

Tarsus Pharmaceuticals, Inc.

CEO	Dr. Bobak R. Azamian M.D.
IPO Date	Oct. 16, 2020
Location	United States
Headquarters	15440 Laguna Canyon Road
Employees	244
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Key trends

Past 5 years